search
Back to results

Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors

Primary Purpose

Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Brain Tumor, Recurrent Childhood Cerebellar Astrocytoma

Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
erlotinib hydrochloride
temozolomide
pharmacological study
laboratory biomarker analysis
Sponsored by
National Cancer Institute (NCI)
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Previously Treated Childhood Rhabdomyosarcoma

Eligibility Criteria

undefined - 21 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: One of the following histologically confirmed solid tumors: Brain tumors Osteogenic sarcoma Rhabdomyosarcoma Soft tissue sarcoma (excluding Ewing's sarcoma) Neuroblastoma Germ cell tumors Recurrent or refractory disease No known curative therapy exists Performance status - Karnofsky 50-100% (for patients age 11 to 21) Performance status - Lansky 50-100% (for patients age 10 and under) At least 8 weeks Absolute neutrophil count > 1,000/mm^3 Platelet count > 100,000/mm^3 (transfusion independent*) Hemoglobin > 8.0 g/dL (transfusion allowed) Bilirubin < 1.5 times upper limit of normal (ULN) ALT < 2.5 times ULN Albumin ≥ 2 g/dL Creatinine clearance or radioisotope glomerular filtration rate at least 70 mL/min Creatinine based on age as follows: ≤ 0.8 mg/dL for patients age 5 and under ≤ 1.0 mg/dL for patients 6 to 10 ≤ 1.2 mg/dL for patients 11 to 15 ≤ 1.5 mg/dL for patients age 15 to 21 Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception Able to swallow tablets (for patients in part 2 only) No uncontrolled infection Recovered from all prior immunotherapy At least 7 days since prior biologic therapy At least 3 months since prior stem cell transplantation and no evidence of active graft-versus-host disease More than 1 week since prior growth factors No concurrent prophylactic growth factor therapy No concurrent immunotherapy No concurrent biologic therapy More than 2 weeks since prior myelosuppressive chemotherapy (4 weeks for nitrosoureas) and recovered No other concurrent chemotherapy No concurrent systemic corticosteroids except for treatment of increased intracranial pressure or symptomatic tumor edema in patients with CNS tumors No concurrent steroids as an antiemetic Concurrent dexamethasone for patients with CNS tumors allowed provided patient has been on a stable or decreasing dose for at least 1 week before study entry Recovered from all prior radiotherapy At least 2 weeks since prior local palliative radiotherapy (small port) At least 6 weeks since prior substantial bone marrow irradiation At least 6 months since prior craniospinal radiotherapy At least 6 months since prior radiotherapy to 50% or more of the pelvis At least 8 weeks since prior standard-fraction radiotherapy for patients with recurrent brain tumors unless there is biopsy proof of recurrent tumor Prior radiosurgery within the past 9 months allowed provided there is documentation of progressive disease by biopsy, positron-emission tomography (PET) scan, or MR spectroscopy No concurrent radiotherapy More than 1 week since prior CYP3A4 inhibitors More than 4 weeks since prior CYP3A4 inducers More than 5 days since prior proton-pump inhibitors More than 2 days since prior H_2 blockers No prior erlotinib No concurrent enzyme-inducing anticonvulsants No concurrent proton-pump inhibitors No concurrent H2 blockers No other concurrent investigational agents Concurrent antacids allowed provided the antacid is not administered 2 hours before, during, and 2 hours after erlotinib administration

Sites / Locations

  • COG Phase I Consortium

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Treatment (erlotinib hydrochloride, temozolomide)

Arm Description

Patients receive oral erlotinib once daily on days 1-28. Beginning with course 2, patients also receive oral temozolomide once daily on days 1-5. Treatment repeats every 28 days for up to 23 courses in the absence of disease progression or unacceptable toxicity.

Outcomes

Primary Outcome Measures

Dose-limiting toxicity (DLT) as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0
Maximum-tolerated dose (MTD) based on the incidence of DLT as assessed by NCI CTCAE version 3.0
Pharmacokinetics of erlotinib hydrochloride

Secondary Outcome Measures

Full Information

First Posted
February 10, 2004
Last Updated
June 4, 2013
Sponsor
National Cancer Institute (NCI)
search

1. Study Identification

Unique Protocol Identification Number
NCT00077454
Brief Title
Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors
Official Title
A Phase I Study of Single Agent OSI-774 (Tarceva) (NSC# 718781, IND# 63383) Followed by OSI-774 With Temozolomide for Patients With Selected Recurrent/Refractory Solid Tumors, Including Brain Tumors
Study Type
Interventional

2. Study Status

Record Verification Date
June 2013
Overall Recruitment Status
Completed
Study Start Date
February 2004 (undefined)
Primary Completion Date
September 2007 (Actual)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
National Cancer Institute (NCI)

4. Oversight

5. Study Description

Brief Summary
This phase I trial is studying the side effects and best dose of erlotinib when given with temozolomide in treating young patients with recurrent or refractory solid tumors. Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving erlotinib with temozolomide may kill more tumor cells.
Detailed Description
PRIMARY OBJECTIVES: I. Determine the maximum tolerated dose of erlotinib in children with recurrent or refractory solid tumors. II. Determine the dose-limiting toxic effects of this drug alone and with temozolomide in these patients. III. Determine the tolerability of this regimen in these patients. IV. Determine the pharmacokinetics of this regimen in these patients. SECONDARY OBJECTIVES: I. Determine, preliminarily, the antitumor activity of this regimen in these patients. OUTLINE: This is a 2-part, multicenter, dose-escalation study of erlotinib. Patients are stratified according to pretreatment (heavily pretreated [received more than 2 prior multiagent myelosuppressive chemotherapy regimens OR received prior craniospinal or pelvic radiotherapy or bone marrow transplantation OR has bone marrow involvement] vs less heavily pretreated).Part 1: Patients receive oral erlotinib once daily on days 1-28. Beginning with course 2, patients also receive oral temozolomide once daily on days 1-5. Treatment repeats every 28 days for up to 23 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of erlotinib during course 1 only until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Part 2: Patients receive erlotinib (at the MTD) and temozolomide as in part 1. PROJECTED ACCRUAL: A total of 9-45 patients (9-24 for part 1 and up to 21 for part 2) will be accrued for this study.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Brain Tumor, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Malignant Germ Cell Tumor, Recurrent Childhood Medulloblastoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Neuroblastoma, Recurrent Osteosarcoma

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
95 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Treatment (erlotinib hydrochloride, temozolomide)
Arm Type
Experimental
Arm Description
Patients receive oral erlotinib once daily on days 1-28. Beginning with course 2, patients also receive oral temozolomide once daily on days 1-5. Treatment repeats every 28 days for up to 23 courses in the absence of disease progression or unacceptable toxicity.
Intervention Type
Drug
Intervention Name(s)
erlotinib hydrochloride
Other Intervention Name(s)
CP-358,774, erlotinib, OSI-774
Intervention Description
Given orally (PO)
Intervention Type
Drug
Intervention Name(s)
temozolomide
Other Intervention Name(s)
SCH 52365, Temodal, Temodar, TMZ
Intervention Description
Given PO
Intervention Type
Other
Intervention Name(s)
pharmacological study
Other Intervention Name(s)
pharmacological studies
Intervention Description
Correlative studies
Intervention Type
Other
Intervention Name(s)
laboratory biomarker analysis
Intervention Description
Correlative studies
Primary Outcome Measure Information:
Title
Dose-limiting toxicity (DLT) as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0
Time Frame
56 days (2 courses)
Title
Maximum-tolerated dose (MTD) based on the incidence of DLT as assessed by NCI CTCAE version 3.0
Time Frame
56 days (2 courses)
Title
Pharmacokinetics of erlotinib hydrochloride
Time Frame
At baseline and at 0.5, 1, 2, 4, 6, 8, and 24 hours of course 1

10. Eligibility

Sex
All
Maximum Age & Unit of Time
21 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: One of the following histologically confirmed solid tumors: Brain tumors Osteogenic sarcoma Rhabdomyosarcoma Soft tissue sarcoma (excluding Ewing's sarcoma) Neuroblastoma Germ cell tumors Recurrent or refractory disease No known curative therapy exists Performance status - Karnofsky 50-100% (for patients age 11 to 21) Performance status - Lansky 50-100% (for patients age 10 and under) At least 8 weeks Absolute neutrophil count > 1,000/mm^3 Platelet count > 100,000/mm^3 (transfusion independent*) Hemoglobin > 8.0 g/dL (transfusion allowed) Bilirubin < 1.5 times upper limit of normal (ULN) ALT < 2.5 times ULN Albumin ≥ 2 g/dL Creatinine clearance or radioisotope glomerular filtration rate at least 70 mL/min Creatinine based on age as follows: ≤ 0.8 mg/dL for patients age 5 and under ≤ 1.0 mg/dL for patients 6 to 10 ≤ 1.2 mg/dL for patients 11 to 15 ≤ 1.5 mg/dL for patients age 15 to 21 Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception Able to swallow tablets (for patients in part 2 only) No uncontrolled infection Recovered from all prior immunotherapy At least 7 days since prior biologic therapy At least 3 months since prior stem cell transplantation and no evidence of active graft-versus-host disease More than 1 week since prior growth factors No concurrent prophylactic growth factor therapy No concurrent immunotherapy No concurrent biologic therapy More than 2 weeks since prior myelosuppressive chemotherapy (4 weeks for nitrosoureas) and recovered No other concurrent chemotherapy No concurrent systemic corticosteroids except for treatment of increased intracranial pressure or symptomatic tumor edema in patients with CNS tumors No concurrent steroids as an antiemetic Concurrent dexamethasone for patients with CNS tumors allowed provided patient has been on a stable or decreasing dose for at least 1 week before study entry Recovered from all prior radiotherapy At least 2 weeks since prior local palliative radiotherapy (small port) At least 6 weeks since prior substantial bone marrow irradiation At least 6 months since prior craniospinal radiotherapy At least 6 months since prior radiotherapy to 50% or more of the pelvis At least 8 weeks since prior standard-fraction radiotherapy for patients with recurrent brain tumors unless there is biopsy proof of recurrent tumor Prior radiosurgery within the past 9 months allowed provided there is documentation of progressive disease by biopsy, positron-emission tomography (PET) scan, or MR spectroscopy No concurrent radiotherapy More than 1 week since prior CYP3A4 inhibitors More than 4 weeks since prior CYP3A4 inducers More than 5 days since prior proton-pump inhibitors More than 2 days since prior H_2 blockers No prior erlotinib No concurrent enzyme-inducing anticonvulsants No concurrent proton-pump inhibitors No concurrent H2 blockers No other concurrent investigational agents Concurrent antacids allowed provided the antacid is not administered 2 hours before, during, and 2 hours after erlotinib administration
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Regina Jakacki
Organizational Affiliation
COG Phase I Consortium
Official's Role
Principal Investigator
Facility Information:
Facility Name
COG Phase I Consortium
City
Arcadia
State/Province
California
ZIP/Postal Code
91006-3776
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors

We'll reach out to this number within 24 hrs